Literature DB >> 19669758

The benefits of molecular pathology in the diagnosis of musculoskeletal disease : part I of a two-part review: soft tissue tumors.

Adrienne M Flanagan1, David Delaney, Paul O'Donnell.   

Abstract

Bone and soft tissue metabolic and neoplastic diseases are increasingly characterized by their molecular signatures. This has resulted from increased knowledge of the human genome, which has contributed to the unraveling of molecular pathways in health and disease. Exploitation of this information has allowed it to be used for practical diagnostic purposes. The aim of the first part of this two-part review is to provide an up-to-date review of molecular genetic investigations that are available and routinely used by specialist musculoskeletal histopathologists in the diagnosis of neoplastic disease. Herein we focus on the benefits of employing well characterized somatic mutations in soft tissue lesions that are commonly employed in diagnostic pathology today. The second part highlights the known somatic and germline mutations implicated in osteoclast-rich lesions of bone, and the genetic changes that disturb phosphate metabolism and result in a variety of musculoskeletal phenotypes. Finally, a brief practical guide of how to use and provide a molecular pathology service is given.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19669758     DOI: 10.1007/s00256-009-0759-x

Source DB:  PubMed          Journal:  Skeletal Radiol        ISSN: 0364-2348            Impact factor:   2.199


  80 in total

1.  Synovial sarcoma with radiological appearances of primitive neuroectodermal tumour/Ewing sarcoma: differentiation by molecular genetic studies.

Authors:  P O'Donnell; T C Diss; J Whelan; A M Flanagan
Journal:  Skeletal Radiol       Date:  2005-10-12       Impact factor: 2.199

2.  Ewing's sarcoma of bone: the detection of specific transcripts in a large, consecutive series of formalin-fixed, decalcified, paraffin-embedded tissue samples using the reverse transcriptase-polymerase chain reaction.

Authors:  D C Mangham; A Williams; D J McMullan; J McClure; V P Sumathi; R J Grimer; A M Davies
Journal:  Histopathology       Date:  2006-03       Impact factor: 5.087

3.  Fusion of the EWS-related gene TAF2N to TEC in extraskeletal myxoid chondrosarcoma.

Authors:  H Sjögren; J Meis-Kindblom; L G Kindblom; P Aman; G Stenman
Journal:  Cancer Res       Date:  1999-10-15       Impact factor: 12.701

4.  GNAS1 mutations occur more commonly than previously thought in intramuscular myxoma.

Authors:  David Delaney; Tim C Diss; Nadege Presneau; Sandra Hing; Fitim Berisha; Bernadine D Idowu; P O'Donnell; John A Skinner; Roberto Tirabosco; Adrienne M Flanagan
Journal:  Mod Pathol       Date:  2009-03-13       Impact factor: 7.842

5.  [Translocation of chromosome 22 in Ewing's sarcoma].

Authors:  A Aurias; C Rimbaut; D Buffe; J Dubousset; A Mazabraud
Journal:  C R Seances Acad Sci III       Date:  1983

6.  Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation.

Authors:  I Panagopoulos; N Mandahl; D Ron; M Höglund; M Nilbert; F Mertens; F Mitelman; P Aman
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

Review 7.  The cancer genome.

Authors:  Michael R Stratton; Peter J Campbell; P Andrew Futreal
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

8.  Clear cell sarcoma of soft tissue: a clinicopathologic, immunohistochemical, and molecular analysis of 33 cases.

Authors:  Masanori Hisaoka; Tsuyoshi Ishida; Tseng-Tong Kuo; Atsuji Matsuyama; Tetsuo Imamura; Kazunori Nishida; Hiroshi Kuroda; Yoshiaki Inayama; Hisashi Oshiro; Hiroshi Kobayashi; Takashi Nakajima; Toshio Fukuda; Keisuke Ae; Hiroshi Hashimoto
Journal:  Am J Surg Pathol       Date:  2008-03       Impact factor: 6.394

9.  Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.

Authors:  J Clark; P J Rocques; A J Crew; S Gill; J Shipley; A M Chan; B A Gusterson; C S Cooper
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

10.  Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors.

Authors:  Claudia Forni; Mario Minuzzo; Emanuela Virdis; Elena Tamborini; Matteo Simone; Michele Tavecchio; Eugenio Erba; Federica Grosso; Alessandro Gronchi; Pierre Aman; Paolo Casali; Maurizio D'Incalci; Silvana Pilotti; Roberto Mantovani
Journal:  Mol Cancer Ther       Date:  2009-02-03       Impact factor: 6.261

View more
  1 in total

1.  Liposclerosing myxofibrous tumor (LSMFT), a study of 33 patients: should it be a distinct entity?

Authors:  Jonathan Dattilo; Edward F McCarthy
Journal:  Iowa Orthop J       Date:  2012
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.